Our Rheumatology Program is part of the Childhood Arthritis & Rheumatology Research Alliance (CARRA), an organization of pediatric rheumatologists committed to advancing the health and quality of life of children with rheumatic diseases, and the Pediatric Rheumatology Collaborative Study Group (PRCSG), a consortium of pediatric rheumatology centers aimed at conducting high-quality clinical trials of therapeutic agents in children with rheumatic diseases.
Through these organizations, we participate in clinical research on new medications, new treatment strategies and quality of life studies.
Research Coordinator: Rosabel Agbayani, M.P.H.
Active Clinical Trials
- Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry (ClinicalTrials.gov Identifier: NCT02418442)
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions. https://www.clinicaltrials.gov/ct2/show/NCT02418442?term=CARRA&rank=2
- CARRA SCORE- Sub-Study- Localized Scleroderma and Systemic Sclerosis Protocol Training
The purpose of SCORE is to collect information from patients with scleroderma and sclerosis in order to learn more about how these diseases start and change over time.
- CARRA PROMOTE Predicting Response of Methotrexate Treatment
A prospective observational cohort study that is investigating predictors of MTX response utilizing the CARRA Registry. Looking at only the first six months on treatment and assessing clinical response through registry clinical data entry and collecting biosample for DNA and MTX polyglutamates.